Lancet: global need for effective and rapid evaluation of new crown vaccine candidates

Novel coronavirus pneumonia journal published in September 2nd, the

ScienceDaily Daily reported September 2nd that the world’s need for effective, rapid and reliable assessment of various new crown vaccine candidates is a comment from the WHO’s expert panel on vaccine unification. < / P > < p > according to the review article, there are three crucial issues in the planning of new crown vaccine trials: first, whether it is necessary to prove not only the efficacy of some vaccines, but also the value of their efficacy; second, whether it is necessary to give priority to not only single vaccine trials but also multiple vaccine trials in the preliminary trials of placebo-controlled vaccines; third, whether it is necessary to determine the efficacy of vaccines After the short-term efficacy, but before the local deployment of the vaccine in the general population, the vaccine group and the placebo group were followed up blindly to evaluate their safety, protection against severe diseases and protection time. < / P > < p > according to the article, the rapid introduction of the new crown vaccine may lead to our widely deployed vaccine actually becoming a weak vaccine. The novel coronavirus pneumonia may continue to deteriorate if the local government misunderstands that the vaccine can significantly reduce the risk of infection or the individuals who vaccinated the vaccine also mistakenly believe that they have acquired immunity. < / P > < p > the deployment of a “barely effective” vaccine may also interfere with the evaluation of other vaccines, as subsequent vaccines have to be compared. If the efficacy of the new vaccine is better than that of the weak vaccine, the researchers will need a larger sample size, and the recognition of its efficacy will be delayed accordingly. What’s more, if the weak vaccine is compared with the weak vaccine, it is likely to make an evaluation of whether one of the vaccines is non inferior, forming the so-called “biological crawling phenomenon”.

commented that novel coronavirus pneumonia is a standard vaccine for vaccination against the placebo. The standard for defining a successful vaccine is stringent enough to avoid the risk of deploying a weak vaccine. In particular, many vaccines against new crown lung disease are being tested and the vaccine efficacy is overestimated. Therefore, the preliminary trial of the new crown vaccine and placebo is not only to seek reliable evidence for the efficacy of the vaccine, but also for valuable vaccine efficacy. < / P > < p > in addition, global multi vaccine trials with shared control groups can provide faster and more reliable results than individual trials for each of many different vaccines. Continuing to use the established clinical trial infrastructure can save time and energy and accelerate the discovery of several safe and effective vaccines. Flexible trial design and hundreds of research sites in high disease incidence areas promote the high enrollment rate of test subjects. After the corresponding vaccine trials are carried out, the short-term efficacy results of each vaccine can be obtained in just a few months. < / P > < p > the article also mentioned that the main outcome indicator of the study was laboratory confirmed symptoms 14 days after vaccination. In any case, placebo-controlled follow-up should last at least 12 months, or until an effective vaccine can be deployed locally, to assess the safety, degree of protection and duration of protection of the vaccine.

novel coronavirus pneumonia, vaccine research institutes and government agencies have signed a statement on international cooperation in vaccine research. All of us hope that the disease, death and destruction caused by the global new crown pneumonia pandemic can be concluded as early as possible.